Enhanced EHR-workflow-integrated communications enable prescribers to act on lower-cost therapeutic alternatives, while reinforcing Scripta’s proven member-drivenEnhanced EHR-workflow-integrated communications enable prescribers to act on lower-cost therapeutic alternatives, while reinforcing Scripta’s proven member-driven

Scripta Insights Expands Clinically Governed Provider Engagement Within Its Rx Navigation Platform

2026/02/10 23:32
4 min read

Enhanced EHR-workflow-integrated communications enable prescribers to act on lower-cost therapeutic alternatives, while reinforcing Scripta’s proven member-driven savings model

BOSTON, Feb. 10, 2026 /PRNewswire/ — Scripta Insights, the doctor-driven, AI-powered pharmacy navigation company that guides self-insured employers, health plans, and their members to prescription savings, has strengthened its provider engagement capabilities through enhanced, secure EHR-workflow-integrated electronic fax communications.

The enhancement enables prescribing clinicians to review clinically equivalent, lower-cost alternatives and approve or decline recommended switches directly within their existing clinical workflows—supporting efficient alignment on potential savings opportunities, while preserving the physician’s clinical judgment and the member experience.

Unlike point solutions that focus on prescriber outreach alone, Scripta’s provider engagement capabilities operate as part of its broader Rx Navigation platform—connecting prescribers, members and plan sponsors through a single, clinically governed system designed to drive both immediate and sustained pharmacy savings.

When a savings opportunity is identified, Scripta delivers recommendations aligned to the employer’s benefit design and formulary directly to the provider, including pricing and therapeutic alternatives. Providers can then approve or decline the recommendation on the member’s behalf, reducing friction for patients and helping avoid prescription abandonment.

Scripta’s provider engagement model is governed by its independent Pharmacy & Therapeutics (P&T) Committee, composed of 30 actively practicing physicians and pharmacists representing 22 clinical specialties. The committee evaluates therapeutic alternatives based on clinical appropriateness, evidence and real-world practice considerations to ensure that recommendations reflect decisions a practicing clinician would reasonably make for their own patients.

This clinical governance model enables:

  • Evidence-based, clinically appropriate recommendations
  • Peer-to-peer physician credibility
  • Higher likelihood of provider adoption and sustained action

“At the end of a long day in the exam room, the last thing a physician wants is a message that simply says ‘change to this medication’ without context,” said Dr. Paul Bradley, Co-Founder and Chief Medical Officer of Scripta Insights. “Scripta’s enhanced provider engagement approach delivers the right information to clinicians at the right time, helping physicians have more informed, productive conversations with their patients—without disrupting how they already practice medicine.”

“Expanding clinically governed provider engagement scales a powerful lever we already use to help plan sponsors drive prescription savings,” said Eric Levin, CEO of Scripta Insights. “Across more than 100 employer and health plan clients, we see the strongest and most durable results when prescribers and members are both supported with clear, personalized guidance. Our Rx Navigation platform brings these capabilities together in a single, end-to-end solution that works within existing benefit designs and vendor ecosystems to help organizations drive meaningful and sustainable pharmacy savings.”

Across its client base, Scripta data shows:

  • Approximately 29 percent of all active members on prescriptions have at least one identified savings opportunity
  • Among active members with identified savings opportunities, 40 percent complete a medication switch that saves
  • Members save an average of $25 per month
  • 93 percent of medication switches driven by Scripta’s clinical recommendations remain in place after 12 months

Scripta’s Rx Navigation platform supports coordinated decision-making across members, prescribers and plan sponsors through tools including member-facing navigation, prescriber engagement, plan sponsor analytics and targeted incentive programs—working alongside any PBM and within a client’s existing benefit design.

Scripta operates as an independent, unbiased third party, delivering clinically governed recommendations, flexible integration and transparent reporting—designed to support plan sponsors in meeting their ERISA fiduciary responsibilities and aligned exclusively to employer and health plan goals.

About Scripta Insights
Scripta Insights is a venture-backed digital health company providing clinically governed pharmacy navigation solutions for self-insured employers, health plans and their members. Founded in 2019, the company’s platform was developed by physicians, pharmacists and data scientists to help stakeholders navigate the growing complexity of prescription benefits and medication decision-making.
For more information, visit www.scriptainsights.com and follow the company on LinkedIn.

Media Contact
Linda Krebs
LKPR, Inc. for Scripta Insights
lk@lkprinc.com
646-824-5186

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/scripta-insights-expands-clinically-governed-provider-engagement-within-its-rx-navigation-platform-302683042.html

SOURCE Scripta Insights

Market Opportunity
The AI Prophecy Logo
The AI Prophecy Price(ACT)
$0.01396
$0.01396$0.01396
-2.85%
USD
The AI Prophecy (ACT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

CME Group to Launch Solana and XRP Futures Options

CME Group to Launch Solana and XRP Futures Options

The post CME Group to Launch Solana and XRP Futures Options appeared on BitcoinEthereumNews.com. An announcement was made by CME Group, the largest derivatives exchanger worldwide, revealed that it would introduce options for Solana and XRP futures. It is the latest addition to CME crypto derivatives as institutions and retail investors increase their demand for Solana and XRP. CME Expands Crypto Offerings With Solana and XRP Options Launch According to a press release, the launch is scheduled for October 13, 2025, pending regulatory approval. The new products will allow traders to access options on Solana, Micro Solana, XRP, and Micro XRP futures. Expiries will be offered on business days on a monthly, and quarterly basis to provide more flexibility to market players. CME Group said the contracts are designed to meet demand from institutions, hedge funds, and active retail traders. According to Giovanni Vicioso, the launch reflects high liquidity in Solana and XRP futures. Vicioso is the Global Head of Cryptocurrency Products for the CME Group. He noted that the new contracts will provide additional tools for risk management and exposure strategies. Recently, CME XRP futures registered record open interest amid ETF approval optimism, reinforcing confidence in contract demand. Cumberland, one of the leading liquidity providers, welcomed the development and said it highlights the shift beyond Bitcoin and Ethereum. FalconX, another trading firm, added that rising digital asset treasuries are increasing the need for hedging tools on alternative tokens like Solana and XRP. High Record Trading Volumes Demand Solana and XRP Futures Solana futures and XRP continue to gain popularity since their launch earlier this year. According to CME official records, many have bought and sold more than 540,000 Solana futures contracts since March. A value that amounts to over $22 billion dollars. Solana contracts hit a record 9,000 contracts in August, worth $437 million. Open interest also set a record at 12,500 contracts.…
Share
BitcoinEthereumNews2025/09/18 01:39
The Silver Price Doesn’t Look Real – And This Video Explains Why

The Silver Price Doesn’t Look Real – And This Video Explains Why

The Silver (XAG) price has been acting strange lately. Just when it looked like the market was settling down, a new argument started spreading fast: silver might
Share
Captainaltcoin2026/02/11 04:00
Ripple CEO Says ‘XRP Will Always Be Top Priority’ as Panic Selling Surges ⋆ ZyCrypto

Ripple CEO Says ‘XRP Will Always Be Top Priority’ as Panic Selling Surges ⋆ ZyCrypto

The post Ripple CEO Says ‘XRP Will Always Be Top Priority’ as Panic Selling Surges ⋆ ZyCrypto appeared on BitcoinEthereumNews.com. Advertisement &nbsp &nbsp Ripple
Share
BitcoinEthereumNews2026/02/11 04:16